Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial-Reference-Cited by-同舟云学术

Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial

Published:2022-03-08 Issue:3 Volume:37 Page:92-101
ISSN:0268-1315
Container-title:International Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Motamed Mahsa,Karimi Hanieh,Sanjari Moghaddam Hossein,Taherzadeh Boroujeni Sina,Sanatian Zahra,Hasanzadeh Alireza,Khodaei Ardakani Mohammad-Reza,Akhondzadeh Shahin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference46 articles.

1. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.;Akhondzadeh;Prog Neuropsychopharmacol Biol Psychiatry,2005

2. Pharmacotherapy of schizophrenia: the past, present and future.;Akhondzadeh;Curr Drug Ther,2006

3. Construction of a neuro-immune-cognitive pathway-phenotype underpinning the phenome of deficit schizophrenia.;Al-Hakeim;Curr Top Med Chem,2020

4. Tumour necrosis factor-alpha mediated mechanisms of cognitive dysfunction.;Baune;Transl Neurosci,2012

5. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.;Benros;Am J Psychiatry,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review;Journal of Affective Disorders;2024-11

2. Therapeutic effectiveness of anti-inflammatory monoclonal antibodies in psychiatric disorders: Challenges with an imbalanced immune system;European Neuropsychopharmacology;2024-11

3. The Interrelationships between Cytokines and Schizophrenia: A Systematic Review;International Journal of Molecular Sciences;2024-08-03

4. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial;Brain, Behavior, and Immunity;2024-01

5. Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits);BMC Psychiatry;2023-10-23